Researchers have uncovered that cancer cells communicate over much greater distances than previously...
UCB takes over Ra Pharma to expand myasthenia gravis offering
Ra Pharmaceuticals focuses on assets that selectively inhibit the complement system and other immune targets, including its lead pipeline drug Zilucoplan.
How do cancer cells communicate and can it help us catch them?
Researchers have uncovered that cancer cells communicate over much greater distances than previously expected, opening up more possibilities for detection. We spoke to the researchers to get the inside track on how our knowledge about the way cancer cells communicate is changing.
From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes
Almost 15 years after the approval of the first GLP-1 agonist, the US FDA has approved the first oral version of this treatment approach for type 2 diabetes. What are the benefits of a pill-based, rather than injectable version, of GLP-1 analogues for this patient population?
Understanding drug-resistant TB
Drug-resistant tuberculosis causes one third of all antimicrobial resistance related deaths, presenting an enormous challenge. The threat is growing and has the potential to spiral out of control as drugs lose all effectiveness, so what can be done? PTF finds out.
Shionogi and Hsiri to develop mycobacterial disease therapies
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as well as tuberculosis (TB).
NICE approves Clovis Oncology’s rucaparib for CDF use
The National Institute for Health and Care Excellence (NICE), UK has approved Clovis Oncology’s ovarian cancer drug rucaparib (Rubraca) for use within the Cancer Drugs Fund (CDF).
UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio
UCB has acquired Massachusetts-based Ra Pharmaceuticals for $48 per share, bringing the total transaction to a value of approximately $2.1bn.
Risk of developing generalised MG is higher in smokers
Smoking increases the risk of generalised myasthenia gravis.
Could anti-coagulants be the key to treating Alzheimer’s disease?
Scientists have discovered that treatment with oral anticoagulant dabigatran may delay the appearance of Alzheimer’s disease.
Amgen enters partnership to use adaptive biotechnologies’ MRD diagnostic assay for haematology drug development
Adaptive Biotechnologies and Amgen agree to assess minimal residual disease (MRD) for multiple drugs within Amgen’s haematology portfolio.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.